AmeriPath Pursues Ambitious Strategy Of Rapid Expansion

CEO SUMMARY: As the pathology profession’s only publicly-traded physician practice management company, AmeriPath is the spear point of far-reaching changes now transforming pathology. With an annual revenue run rate of $270 million and an ample war chest of growth capital, AmeriPath intends to continue its steady expansion. In the 28 months since its initial public …

AmeriPath Pursues Ambitious Strategy Of Rapid Expansion Read More »

To access this post, you must purchase The Dark Report.

AmeriPath Pursues Ambitious Strategy Of Rapid Expansion

Acquired $49.0 Million of Path Practices in 1999

Comments

TABLE OF CONTENTS

Need A Group Membership? Company Discounts are Available!

You are reading premium content from The Dark Report, your primary resource for running an efficient and profitable laboratory.

Get Unlimited Access to The Dark Report absolutely FREE!

You have read 0 of 1 of your complimentary articles this month

You have read 0 of 1 of your complimentary articles this month